Ensuring Leadership Continuity—The Coleman Health Services Case Study is starting in

Centene Divests Magellan Rx To Prime Therapeutics For $1.35 Billion

Pharmacy benefit manager (PBM) Prime Therapeutics LLC (Prime) finalized its previously announced $1.35 bilion acquisition of Magellan Rx Management, (Magellan Rx), the pharmacy division of Magellan Health, from Centene Corporation. The agreement unites Prime’s strong foundation of pharmacy benefit management (PBM) capabilities with Magellan Rx’s industry-leading total specialty drug management expertise to create a diversified pharmacy solutions organization serving commercial markets and government programs.

Integration planning for the two companies is underway. Both brands will remain in the market for up to a year as the company explores new brand opportunities that convey the innovation, energy . . .

Want To Read More? Log In Or Become A Free Member
Resource Available For All OPEN MINDS Circle Members
If you are already a member, log in to your account to access this resource and more.

You can become a free member and get access now. Learn more about the OPEN MINDS Circle Market Intelligence Service Membership. Reach out to our team at info@openminds.com, or call us at 877-350-6463.

A Paid OPEN MINDS Circle Membership provides unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!